Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2023 Annual General Meeting
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Dec 07, 2018 4:45pm EST

Lexaria Bioscience Expands Staff, Issues Options

Nov 26, 2018 6:30am EST

Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer

Nov 13, 2018 6:05am EST

Lexaria Bioscience Launches ChrgD+

Oct 31, 2018 1:30pm EDT

Lexaria Bioscience Announces Increased Size and Closing of Private Placement

Oct 23, 2018 9:00am EDT

Lexaria Bioscience Corp. Discusses The Importance of New Subsidiaries and Intellectual Property with Uptick Newswire’s Stock Day Podcast

Oct 18, 2018 6:10am EDT

Lexaria Bioscience Receives Two New Granted Patents

Oct 10, 2018 6:05am EDT

Lexaria Bioscience Creates and Brands Subsidiary Companies

Sep 28, 2018 6:10am EDT

Lexaria Files New Patent Application for Delivery of Tobacco-Derived Products

Sep 07, 2018 6:34am EDT

Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance

Aug 30, 2018 6:30am EDT

Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top